Cover Image
市場調查報告書

Integrated BioTherapeutics, Inc.的產品平台分析

Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251676
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Integrated BioTherapeutics, Inc.的產品平台分析 Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016
出版日期: 2016年02月29日 內容資訊: 英文 34 Pages
簡介

Integrated BioTherapeutics, Inc.是總公司在美國的生物科技企業。進行新興感染疾病治療用疫苗和藥物的藥物研發及開發。除了產品以外,也提供in vitro及in vivo篩檢、動物模式的開發、化驗開發、免疫抗原性實驗、血清學實驗。

本報告提供Integrated BioTherapeutics, Inc. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Integrated BioTherapeutics, Inc. 的基本資料

  • Integrated BioTherapeutics, Inc. 概要
  • 主要資訊
  • 企業資料

Integrated BioTherapeutics, Inc. :R&D概要

  • 主要的治療範圍

Integrated BioTherapeutics, Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Integrated BioTherapeutics, Inc. :開發中產品概況

  • 在臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Integrated BioTherapeutics, Inc. :藥物簡介

  • STEBVax
  • AT-62-aa
  • Monoclonal Antibody 3 for Staphylococcus Aureus Infections
  • panfilovirus (multivalent) vaccine
  • SEB-HuMab
  • staphylococcal serogroup A (multivalent) vaccine
  • staphylococcus aureus (bivalent) vaccine
  • staphylococcus aureus (multivalent) vaccine
  • Monoclonal Antibodies for Ebola and Marburg Infections
  • Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV
  • Monoclonal Antibody 1 for Staphylococcus Aureus Infections
  • Monoclonal Antibody 2 for Staphylococcus Aureus Infections
  • Monoclonal Antibody 4 for Staphylococcus Aureus Infections

Integrated BioTherapeutics, Inc. :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Integrated BioTherapeutics, Inc. :最近的開發平台資訊

Integrated BioTherapeutics, Inc. :開發休止的計劃

Integrated BioTherapeutics, Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07973CDB

Summary

Global Markets Direct's, 'Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the Integrated BioTherapeutics, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Integrated BioTherapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Integrated BioTherapeutics, Inc.
  • The report provides overview of Integrated BioTherapeutics, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Integrated BioTherapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Integrated BioTherapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Integrated BioTherapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Integrated BioTherapeutics, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrated BioTherapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Integrated BioTherapeutics, Inc. Snapshot
    • Integrated BioTherapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Integrated BioTherapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Integrated BioTherapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Integrated BioTherapeutics, Inc. - Pipeline Products Glance
    • Integrated BioTherapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Integrated BioTherapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Integrated BioTherapeutics, Inc. - Drug Profiles
    • STEBVax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (Ebola + Marburg) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibodies for Ebola and Marburg Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-62aa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Ebola and Marburg Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Equine Encephalitis and Chikungunya
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 1 for Staphylococcus Aureus Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Integrated BioTherapeutics, Inc. - Pipeline Analysis
    • Integrated BioTherapeutics, Inc. - Pipeline Products by Target
    • Integrated BioTherapeutics, Inc. - Pipeline Products by Route of Administration
    • Integrated BioTherapeutics, Inc. - Pipeline Products by Molecule Type
    • Integrated BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Integrated BioTherapeutics, Inc. - Recent Pipeline Updates
  • Integrated BioTherapeutics, Inc. - Dormant Projects
  • Integrated BioTherapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Integrated BioTherapeutics, Inc., Key Information
  • Integrated BioTherapeutics, Inc., Key Facts
  • Integrated BioTherapeutics, Inc. - Pipeline by Indication, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline by Stage of Development, 2016
  • Integrated BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • Integrated BioTherapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Integrated BioTherapeutics, Inc. - Phase I, 2016
  • Integrated BioTherapeutics, Inc. - Preclinical, 2016
  • Integrated BioTherapeutics, Inc. - Discovery, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline by Target, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline by Route of Administration, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline by Molecule Type, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Integrated BioTherapeutics, Inc. - Recent Pipeline Updates, 2016
  • Integrated BioTherapeutics, Inc. - Dormant Developmental Projects,2016

List of Figures

  • Integrated BioTherapeutics, Inc. - Pipeline by Indication, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline by Stage of Development, 2016
  • Integrated BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline by Target, 2016
  • Integrated BioTherapeutics, Inc. - Pipeline by Molecule Type, 2016
Back to Top